Peptide immunogens provide an approach to focus antibody responses to specific neutralizing sites on the HIV envelope protein (Env) trimer or on other pathogens. However, the physical characteristics of peptide immunogens can limit their pharmacokinetic and immunological properties. Here, we have designed synthetic "star" nanoparticles based on biocompatible N-[(2-hydroxypropyl)methacrylamide] (HPMA)-based polymer arms extending from a poly(amidoamine) (PAMAM) dendrimer core. In mice, these star nanoparticles trafficked to lymph nodes (LNs) by 4 hours following vaccination, where they were taken up by subcapsular macrophages and then resident dendritic cells (DCs). Immunogenicity optimization studies revealed a correlation of immunogen density with antibody titers. Furthermore, the co-delivery of Env variable loop 3 (V3) and T-helper peptides induced titers that were 2 logs higher than if the peptides were given in separate nanoparticles. Finally, we performed a nonhuman primate (NHP) study using a V3 glycopeptide minimal immunogen that was structurally optimized to be recognized by Env V3/glycan broadly neutralizing antibodies (bnAbs). When administered with a potent Toll-like receptor (TLR) 7/8 agonist adjuvant, these nanoparticles elicited high antibody binding titers to the V3 site. Similar to human V3/glycan bnAbs, certain monoclonal antibodies (mAbs) elicited by this vaccine were glycan dependent or targeted the GDIR peptide motif. To improve affinity to native Env trimer affinity, nonhuman primates (NHPs) were boosted with various SOSIP Env proteins; however, significant neutralization was not observed. Taken together, this study provides a new vaccine platform for administration of glycopeptide immunogens for focusing immune responses to specific bnAb epitopes.

Avidea Technologies Inc Baltimore Maryland United States of America

Department of Chemical Biology Memorial Sloan Kettering Cancer Center New York New York United States of America

Duke Human Vaccine Institute Duke University School of Medicine Durham North Carolina United States of America

Electron Microscopy Laboratory Cancer Research Technology Program Leidos Biomedical Research Inc Frederick National Laboratory for Cancer Research Frederick Maryland United States of America

Institute of Macromolecular Chemistry Czech Academy of Sciences Prague Czech Republic

Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda Maryland United States of America

See more in PubMed

Kwong PD, Mascola JR, Nabel GJ. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nature reviews Immunology. 2013;13(9):693–701. 10.1038/nri3516 . PubMed DOI

Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. The New England journal of medicine. 2009;361(23):2209–20. 10.1056/NEJMoa0908492 . PubMed DOI

Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. The Journal of infectious diseases. 2006;194(12):1661–71. 10.1086/508748 . PubMed DOI

Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. The Journal of infectious diseases. 2005;191(5):654–65. 10.1086/428404 . PubMed DOI

Hraber P, Seaman MS, Bailer RT, Mascola JR, Montefiori DC, Korber BT. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. Aids. 2014;28(2):163–9. 10.1097/QAD.0000000000000106 . PubMed DOI PMC

Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 2011;7(1):e1001251 10.1371/journal.ppat.1001251 . PubMed DOI PMC

Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol. 2011;85(10):4828–40. 10.1128/JVI.00198-11 . PubMed DOI PMC

Shingai M, Donau OK, Plishka RJ, Buckler-White A, Mascola JR, Nabel GJ, et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med. 2014;211(10):2061–74. 10.1084/jem.20132494 . PubMed DOI PMC

Saunders KO, Pegu A, Georgiev IS, Zeng M, Joyce MG, Yang ZY, et al. Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. J Virol. 2015;89(11):5895–903. 10.1128/JVI.00210-15 . PubMed DOI PMC

Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K, Weisgrau KL, et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A. 2012;109(46):18921–5. 10.1073/pnas.1214785109 . PubMed DOI PMC

Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N, et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 2013;9(9):e1003618 10.1371/journal.ppat.1003618 . PubMed DOI PMC

Yasmeen A, Ringe R, Derking R, Cupo A, Julien JP, Burton DR, et al. Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology. 2014;11:41 10.1186/1742-4690-11-41 . PubMed DOI PMC

Klasse PJ, LaBranche CC, Ketas TJ, Ozorowski G, Cupo A, Pugach P, et al. Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. PLoS Pathog. 2016;12(9):e1005864 10.1371/journal.ppat.1005864 . PubMed DOI PMC

Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, et al. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science. 2015;349(6244):aac4223. 10.1126/science.aac4223 . PubMed DOI PMC

de Taeye SW, Ozorowski G, Torrents de la Pena A, Guttman M, Julien JP, van den Kerkhof TL, et al. Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. Cell. 2015;163(7):1702–15. Epub 2015/12/22. 10.1016/j.cell.2015.11.056 . PubMed DOI PMC

Pauthner M, Havenar-Daughton C, Sok D, Nkolola JP, Bastidas R, Boopathy AV, et al. Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. Immunity. 2017;46(6):1073–88 e6. 10.1016/j.immuni.2017.05.007 . PubMed DOI PMC

Voss JE, Andrabi R, McCoy LE, de Val N, Fuller RP, Messmer T, et al. Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model. Cell Rep. 2017;21(1):222–35. 10.1016/j.celrep.2017.09.024 . PubMed DOI PMC

Xiao X, Chen W, Feng Y, Zhu Z, Prabakaran P, Wang Y, et al. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun. 2009;390(3):404–9. 10.1016/j.bbrc.2009.09.029 . PubMed DOI PMC

Medina-Ramirez M, Garces F, Escolano A, Skog P, de Taeye SW, Del Moral-Sanchez I, et al. Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. J Exp Med. 2017;214(9):2573–90. 10.1084/jem.20161160 . PubMed DOI PMC

de Taeye SW, Torrents de la Pena A, Vecchione A, Scutigliani E, Sliepen K, Burger JA, et al. Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers. J Biol Chem. 2017. 10.1074/jbc.RA117.000709 . PubMed DOI PMC

Julien JP, Lee PS, Wilson IA. Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Immunol Rev. 2012;250(1):180–98. 10.1111/imr.12005 . PubMed DOI PMC

Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O, McGuire A, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science. 2013;340(6133):711–6. 10.1126/science.1234150 . PubMed DOI PMC

Jardine JG, Kulp DW, Havenar-Daughton C, Sarkar A, Briney B, Sok D, et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science. 2016;351(6280):1458–63. 10.1126/science.aad9195 . PubMed DOI PMC

Jardine JG, Ota T, Sok D, Pauthner M, Kulp DW, Kalyuzhniy O, et al. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science. 2015;349(6244):156–61. . PubMed PMC

Sok D, Briney B, Jardine JG, Kulp DW, Menis S, Pauthner M, et al. Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. Science. 2016;353(6307):1557–60. 10.1126/science.aah3945 . PubMed DOI PMC

Mascola JR, Haynes BF. HIV-1 neutralizing antibodies: understanding nature’s pathways. Immunol Rev. 2013;254(1):225–44. 10.1111/imr.12075 . PubMed DOI PMC

Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell. 2013;153(1):126–38. 10.1016/j.cell.2013.03.018 . PubMed DOI PMC

Aussedat B, Vohra Y, Park PK, Fernandez-Tejada A, Alam SM, Dennison SM, et al. Chemical Synthesis of Highly Congested gp120 V1V2 N-Glycopeptide Antigens for Potential HIV-1-Directed Vaccines. Journal of the American Chemical Society. 2013;135(35):13113–20. 10.1021/ja405990z PubMed DOI PMC

Alam SM, Aussedat B, Vohra Y, Meyerhoff RR, Cale EM, Walkowicz WE, et al. Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. Sci Transl Med. 2017;9(381). 10.1126/scitranslmed.aai7521 . PubMed DOI PMC

Cai H, Orwenyo J, Guenaga J, Giddens J, Toonstra C, Wyatt RT, et al. Synthetic multivalent V3 glycopeptides display enhanced recognition by glycan-dependent HIV-1 broadly neutralizing antibodies. Chem Commun (Camb). 2017;53(39):5453–6. 10.1039/c7cc02059g . PubMed DOI PMC

Kong R, Xu K, Zhou T, Acharya P, Lemmin T, Liu K, et al. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science. 2016;352(6287):828–33. 10.1126/science.aae0474 . PubMed DOI PMC

Xu K, Acharya P, Kong R, Cheng C, Chuang GY, Liu K, et al. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nat Med. 2018;24(6):857–67. Epub 2018/06/06. 10.1038/s41591-018-0042-6 . PubMed DOI PMC

Alam SM, Dennison SM, Aussedat B, Vohra Y, Park PK, Fernandez-Tejada A, et al. Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. P Natl Acad Sci USA. 2013;110(45):18214–9. 10.1073/pnas.1317855110 PubMed DOI PMC

Bonsignori M, Kreider EF, Fera D, Meyerhoff RR, Bradley T, Wiehe K, et al. Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. Sci Transl Med. 2017;9(381). 10.1126/scitranslmed.aai7514 . PubMed DOI PMC

Di Pasquale A, Preiss S, Tavares Da Silva F, Garcon N. Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines (Basel). 2015;3(2):320–43. 10.3390/vaccines3020320 . PubMed DOI PMC

Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014;509(7498):55–62. 10.1038/nature13036 . PubMed DOI PMC

Kong R, Louder MK, Wagh K, Bailer RT, deCamp A, Greene K, et al. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. J Virol. 2015;89(5):2659–71. 10.1128/JVI.03136-14 . PubMed DOI PMC

Lynn GM, Laga R, Darrah PA, Ishizuka AS, Balaci AJ, Dulcey AE, et al. In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nat Biotechnol. 2015;33(11):1201–10. 10.1038/nbt.3371 . PubMed DOI PMC

Francica JR, Lynn GM, Laga R, Joyce MG, Ruckwardt TJ, Morabito KM, et al. Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant. Bioconjug Chem. 2016;27(10):2372–85. 10.1021/acs.bioconjchem.6b00370 . PubMed DOI

Sharon M, Gorlach M, Levy R, Hayek Y, Anglister J. Expression, purification, and isotope labeling of a gp120 V3 peptide and production of a Fab from a HIV-1 neutralizing antibody for NMR studies. Protein Expr Purif. 2002;24(3):374–83. 10.1006/prep.2001.1577 . PubMed DOI

Gorny MK, Conley AJ, Karwowska S, Buchbinder A, Xu JY, Emini EA, et al. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol. 1992;66(12):7538–42. Epub 1992/12/01. . PubMed PMC

Junt T, Moseman EA, Iannacone M, Massberg S, Lang PA, Boes M, et al. Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells. Nature. 2007;450(7166):110–4. 10.1038/nature06287 . PubMed DOI

Gaya M, Castello A, Montaner B, Rogers N, Reis e Sousa C, Bruckbauer A, et al. Host response. Inflammation-induced disruption of SCS macrophages impairs B cell responses to secondary infection. Science. 2015;347(6222):667–72. . PubMed

Desbien AL, Dubois Cauwelaert N, Reed SJ, Bailor HR, Liang H, Carter D, et al. IL-18 and Subcapsular Lymph Node Macrophages are Essential for Enhanced B Cell Responses with TLR4 Agonist Adjuvants. Journal of immunology. 2016;197(11):4351–9. 10.4049/jimmunol.1600993 . PubMed DOI PMC

Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity. 1994;1(9):751–61. Epub 1994/12/01. . PubMed

Francica JR, Zak DE, Linde C, Siena E, Johnson C, Juraska M, et al. Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. Blood Adv. 2017;1(25):2329–42. Epub 2018/01/04. 10.1182/bloodadvances.2017011411 S.J., and D.T.O. were employees of Novartis Vaccines at this study’s conception. The remaining authors declare no competing financial interests. PubMed DOI PMC

Buonsanti C, Balocchi C, Harfouche C, Corrente F, Galli Stampino L, Mancini F, et al. Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines. Sci Rep. 2016;6:29063 Epub 2016/07/22. 10.1038/srep29063 . PubMed DOI PMC

Moyer TJ, Zmolek AC, Irvine DJ. Beyond antigens and adjuvants: formulating future vaccines. J Clin Invest. 2016;126(3):799–808. Epub 2016/03/02. 10.1172/JCI81083 . PubMed DOI PMC

Saunders KO, Verkoczy LK, Jiang C, Zhang J, Parks R, Chen H, et al. Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. Cell Rep. 2017;21(13):3681–90. Epub 2017/12/28. 10.1016/j.celrep.2017.12.028 . PubMed DOI PMC

Garces F, Sok D, Kong L, McBride R, Kim HJ, Saye-Francisco KF, et al. Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell. 2014;159(1):69–79. 10.1016/j.cell.2014.09.009 . PubMed DOI PMC

Zolla-Pazner S, Kong XP, Jiang X, Cardozo T, Nadas A, Cohen S, et al. Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. J Virol. 2011;85(19):9887–98. 10.1128/JVI.05086-11 . PubMed DOI PMC

Tagliamonte M, Marasco D, Ruggiero A, De Stradis A, Tornesello ML, Totrov M, et al. HIV p24 as scaffold for presenting conformational HIV Env antigens. PLoS ONE. 2012;7(8):e43318 10.1371/journal.pone.0043318 . PubMed DOI PMC

Totrov M, Jiang X, Kong XP, Cohen S, Krachmarov C, Salomon A, et al. Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. Virology. 2010;405(2):513–23. 10.1016/j.virol.2010.06.027 . PubMed DOI PMC

Zhou T, Zhu J, Yang Y, Gorman J, Ofek G, Srivatsan S, et al. Transplanting supersites of HIV-1 vulnerability. PLoS ONE. 2014;9(7):e99881 10.1371/journal.pone.0099881 . PubMed DOI PMC

Dosenovic P, von Boehmer L, Escolano A, Jardine J, Freund NT, Gitlin AD, et al. Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Cell. 2015;161(7):1505–15. 10.1016/j.cell.2015.06.003 . PubMed DOI PMC

Escolano A, Steichen JM, Dosenovic P, Kulp DW, Golijanin J, Sok D, et al. Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice. Cell. 2016;166(6):1445–58 e12. 10.1016/j.cell.2016.07.030 . PubMed DOI PMC

McGuire AT, Gray MD, Dosenovic P, Gitlin AD, Freund NT, Petersen J, et al. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nature communications. 2016;7:10618 10.1038/ncomms10618 . PubMed DOI PMC

Tian M, Cheng C, Chen X, Duan H, Cheng HL, Dao M, et al. Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. Cell. 2016;166(6):1471–84 e18. 10.1016/j.cell.2016.07.029 . PubMed DOI PMC

Gujer C, Sundling C, Seder RA, Karlsson Hedestam GB, Lore K. Human and rhesus plasmacytoid dendritic cell and B-cell responses to Toll-like receptor stimulation. Immunology. 2011;134(3):257–69. 10.1111/j.1365-2567.2011.03484.x . PubMed DOI PMC

Morgan C, Marthas M, Miller C, Duerr A, Cheng-Mayer C, Desrosiers R, et al. The use of nonhuman primate models in HIV vaccine development. PLoS Med. 2008;5(8):e173 10.1371/journal.pmed.0050173 . PubMed DOI PMC

Ketloy C, Engering A, Srichairatanakul U, Limsalakpetch A, Yongvanitchit K, Pichyangkul S, et al. Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates. Veterinary immunology and immunopathology. 2008;125(1–2):18–30. 10.1016/j.vetimm.2008.05.001 . PubMed DOI

Havenar-Daughton C, Lee JH, Crotty S. Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem. Immunol Rev. 2017;275(1):49–61. 10.1111/imr.12512 . PubMed DOI

Madaan K, Kumar S, Poonia N, Lather V, Pandita D. Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci. 2014;6(3):139–50. 10.4103/0975-7406.130965 . PubMed DOI PMC

Wang D, Kopeckova JP, Minko T, Nanayakkara V, Kopecek J. Synthesis of starlike N-(2-hydroxypropyl)methacrylamide copolymers: potential drug carriers. Biomacromolecules. 2000;1(3):313–9. Epub 2001/11/17. . PubMed

Kulhari H, Pooja D, Shrivastava S, Kuncha M, Naidu VG, Bansal V, et al. Trastuzumab-grafted PAMAM dendrimers for the selective delivery of anticancer drugs to HER2-positive breast cancer. Sci Rep. 2016;6:23179. 10.1038/srep23179 . PubMed DOI PMC

Zhou X, Zheng Q, Wang C, Xu J, Wu JP, Kirk TB, et al. Star-Shaped Amphiphilic Hyperbranched Polyglycerol Conjugated with Dendritic Poly(l-lysine) for the Codelivery of Docetaxel and MMP-9 siRNA in Cancer Therapy. ACS Appl Mater Interfaces. 2016;8(20):12609–19. 10.1021/acsami.6b01611 . PubMed DOI

Rupp R, Rosenthal SL, Stanberry LR. VivaGel (SPL7013 Gel): a candidate dendrimer—microbicide for the prevention of HIV and HSV infection. Int J Nanomedicine. 2007;2(4):561–6. . PubMed PMC

McGowan I, Gomez K, Bruder K, Febo I, Chen BA, Richardson BA, et al. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). Aids. 2011;25(8):1057–64. 10.1097/QAD.0b013e328346bd3e . PubMed DOI PMC

Kobayashi H, Kawamoto S, Jo SK, Bryant HL Jr., Brechbiel MW, Star RA. Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. Bioconjug Chem. 2003;14(2):388–94. 10.1021/bc025633c . PubMed DOI

Etrych T, Subr V, Laga R, Rihova B, Ulbrich K. Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours. Eur J Pharm Sci. 2014;58:1–12. 10.1016/j.ejps.2014.02.016 . PubMed DOI

Laga R, Janouskova O, Ulbrich K, Pola R, Blazkova J, Filippov SK, et al. Thermoresponsive Polymer Micelles as Potential Nanosized Cancerostatics. Biomacromolecules. 2015;16(8):2493–505. 10.1021/acs.biomac.5b00764 . PubMed DOI

Zhang L, Fang Y, Kopecek J, Yang J. A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin’s lymphomas. Eur J Pharm Sci. 2017;103:36–46. Epub 2017/03/03. 10.1016/j.ejps.2017.02.034 . PubMed DOI

Pechar M, Pola R, Laga R, Braunova A, Filippov SK, Bogomolova A, et al. Coiled coil peptides and polymer-peptide conjugates: synthesis, self-assembly, characterization and potential in drug delivery systems. Biomacromolecules. 2014;15(7):2590–9. Epub 2014/05/27. 10.1021/bm500436p . PubMed DOI

Carlisle R, Choi J, Bazan-Peregrino M, Laga R, Subr V, Kostka L, et al. Enhanced tumor uptake and penetration of virotherapy using polymer stealthing and focused ultrasound. J Natl Cancer Inst. 2013;105(22):1701–10. Epub 2013/10/31. 10.1093/jnci/djt305 . PubMed DOI PMC

Johnson RN, Chu DS, Shi J, Schellinger JG, Carlson PM, Pun SH. HPMA-oligolysine copolymers for gene delivery: optimization of peptide length and polymer molecular weight. J Control Release. 2011;155(2):303–11. Epub 2011/07/26. 10.1016/j.jconrel.2011.07.009 . PubMed DOI PMC

Wilson DS, Hirosue S, Raczy MM, Bonilla-Ramirez L, Jeanbart L, Wang R, et al. Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity. Nat Mater. 2019;18(2):175–85. Epub 2019/01/16. 10.1038/s41563-018-0256-5 . PubMed DOI

Bennett NR, Zwick DB, Courtney AH, Kiessling LL. Multivalent Antigens for Promoting B and T Cell Activation. ACS Chem Biol. 2015;10(8):1817–24. 10.1021/acschembio.5b00239 . PubMed DOI PMC

Lopez-Sagaseta J, Malito E, Rappuoli R, Bottomley MJ. Self-assembling protein nanoparticles in the design of vaccines. Comput Struct Biotechnol J. 2016;14:58–68. 10.1016/j.csbj.2015.11.001 . PubMed DOI PMC

Cai H, Orwenyo J, Giddens JP, Yang Q, Zhang R, LaBranche CC, et al. Synthetic Three-Component HIV-1 V3 Glycopeptide Immunogens Induce Glycan-Dependent Antibody Responses. Cell Chem Biol. 2017. 10.1016/j.chembiol.2017.09.005 . PubMed DOI PMC

Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science. 2011;334(6059):1097–103. 10.1126/science.1213256 . PubMed DOI PMC

Sok D, Pauthner M, Briney B, Lee JH, Saye-Francisco KL, Hsueh J, et al. A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans. Immunity. 2016;45(1):31–45. 10.1016/j.immuni.2016.06.026 . PubMed DOI PMC

Saunders KO, Nicely NI, Wiehe K, Bonsignori M, Meyerhoff RR, Parks R, et al. Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. Cell Rep. 2017;18(9):2175–88. 10.1016/j.celrep.2017.02.003 . PubMed DOI PMC

Tran K, Poulsen C, Guenaga J, de Val N, Wilson R, Sundling C, et al. Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Proc Natl Acad Sci U S A. 2014;111(7):E738–47. 10.1073/pnas.1319512111 . PubMed DOI PMC

Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science. 2010;329(5993):811–7. 10.1126/science.1192819 . PubMed DOI PMC

Tran EE, Borgnia MJ, Kuybeda O, Schauder DM, Bartesaghi A, Frank GA, et al. Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog. 2012;8(7):e1002797 10.1371/journal.ppat.1002797 . PubMed DOI PMC

Kong L, Lee JH, Doores KJ, Murin CD, Julien JP, McBride R, et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nature structural & molecular biology. 2013;20(7):796–803. 10.1038/nsmb.2594 . PubMed DOI PMC

Pancera M, Yang Y, Louder MK, Gorman J, Lu G, McLellan JS, et al. N332-Directed broadly neutralizing antibodies use diverse modes of HIV-1 recognition: inferences from heavy-light chain complementation of function. PLoS ONE. 2013;8(2):e55701 10.1371/journal.pone.0055701 . PubMed DOI PMC

Zhou T, Doria-Rose NA, Cheng C, Stewart-Jones GBE, Chuang GY, Chambers M, et al. Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. Cell Rep. 2017;19(4):719–32. Epub 2017/04/27. 10.1016/j.celrep.2017.04.013 . PubMed DOI PMC

Quinn KM, Da Costa A, Yamamoto A, Berry D, Lindsay RW, Darrah PA, et al. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. Journal of immunology. 2013;190(6):2720–35. 10.4049/jimmunol.1202861 . PubMed DOI PMC

Francica JR, Sheng Z, Zhang Z, Nishimura Y, Shingai M, Ramesh A, et al. Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization. Nature communications. 2015;6:6565 10.1038/ncomms7565 . PubMed DOI PMC

Mason RD, Welles HC, Adams C, Chakrabarti BK, Gorman J, Zhou T, et al. Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability. PLoS Pathog. 2016;12(4):e1005537 10.1371/journal.ppat.1005537 . PubMed DOI PMC

Amodio D, Cotugno N, Macchiarulo G, Rocca S, Dimopoulos Y, Castrucci MR, et al. Quantitative Multiplexed Imaging Analysis Reveals a Strong Association between Immunogen-Specific B Cell Responses and Tonsillar Germinal Center Immune Dynamics in Children after Influenza Vaccination. Journal of immunology. 2018;200(2):538–50. 10.4049/jimmunol.1701312 . PubMed DOI PMC

Petrovas C, Ferrando-Martinez S, Gerner MY, Casazza JP, Pegu A, Deleage C, et al. Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies. Sci Transl Med. 2017;9(373). 10.1126/scitranslmed.aag2285 . PubMed DOI PMC

Synthesis and Structure Optimization of Star Copolymers as Tunable Macromolecular Carriers for Minimal Immunogen Vaccine Delivery

Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies